title: Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits?
abstract: The number of people suffering from metabolic disorders is dramatically increasing worldwide. The need for new therapeutic strategies to combat this growing epidemic of metabolic diseases is therefore also increasing. In 2003, resveratrol was discovered to be a small molecule activator of sirtuin 1 (SIRT1), an important molecular target regulating cellular energy metabolism and mitochondrial homeostasis. Rodent studies have clearly demonstrated the potential of resveratrol to improve various metabolic health parameters. To date, however, only limited clinical data are available that have systematically examined the health benefits of resveratrol in metabolically challenged humans. This short review will give an overview of the currently available clinical studies examining the effects of resveratrol on obesity and type 2 diabetes from a human perspective.
authors.affiliation: Department of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands.
authors.forename: Silvie
authors.initials: S
authors.lastname: Timmers
authors.forename: Matthijs K C
authors.initials: MK
authors.lastname: Hesselink
authors.forename: Patrick
authors.initials: P
authors.lastname: Schrauwen
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007342:Insurance Benefits / Q000379:methods; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D013267:Stilbenes; D000077185:Resveratrol
keywords: mitochondria; obesity; resveratrol; sirtuins; type 2 diabetes